Skip to content
OpenCapital
Get started

Aurinia Pharmaceuticals AUPH Retained Earnings

Retained Earnings at other companies

Rogers Corporation logo
Rogers CorporationROG
$1.12B-4.7%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$881.9M-71.9%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$6.39M+108%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$4.72B-14.8%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$660.82M-177%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
-$439.55M+14.3%

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.3B+78.5%
Enterprise value$2.34B+78.3%
P/E7.7×-24.6×
P/S7.7×+2.5×

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's retained earnings?
Aurinia Pharmaceuticals (AUPH) reported retained earnings of -$615.01M in Q1 2026.
How has Aurinia Pharmaceuticals's retained earnings changed year-over-year?
Aurinia Pharmaceuticals's retained earnings increased by 32.7% year-over-year, from -$913.23M to -$615.01M.
What is the long-term trend for Aurinia Pharmaceuticals's retained earnings?
Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's retained earnings has grown at a 2.5% compound annual growth rate (CAGR), from -$575.16M to -$649.37M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.